Monday 18 April 2016, Amsterdam
The Pulmonary Arterial Hypertension (PAH) therapeutics market will experience modest growth from $3.45 billion in 2014 to $4.75 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 3.2%.
The company’s latest report* states that the increase in PAH treatment sales, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by new drug launches, the increased use of double and triple combination therapies, and patient assistance programs by manufacturers.
Lakshmi Dharmarajan, Ph.D., The key player Senior Analyst covering Cardiovascular and Metabolic Disorders, says that despite these developments and growth in the PAH arena, significant unmet needs will remain by 2024, the most crucial of which is to find a cure for the fatal disease.
Dharmarajan explains: “While there are currently 12 marketed PAH therapies available, they only serve to slow disease progression. There is no marketed drug that addresses the underlying disease mechanism and targets to cure patients.
“The main challenges in developing curative or stabilizing therapies come from a lack of understanding of the disease mechanism. This is not helped by the fact that most companies in the field are focusing their attention on reformulating existing PAH drugs and enhancing patient convenience, rather than improving efficacy.”
The analyst adds that there is a great need to develop biomarkers and assays that could be used to predict patient response upfront and make treatment more personalized. However, there are no ongoing efforts to address this need in the PAH therapeutics market.
In terms of what the PAH treatment pipeline does have to offer, there are only two drugs in late-stage clinical development.
Dharmarajan continues: “The more promising of the two late-stage pipeline PAH drugs is Actelion’s Uptravi, a first-in-class prostacyclin IP receptor agonist with a favorable clinical efficacy and safety profile. Uptravi was recently launched in the US in January 2016 and is estimated to be the highest revenue generator of the PAH market at the end of the forecast period, recording near-blockbuster sales of $996 million in 2024.
“The other Phase III candidate, Beraprost sodium 314d, does not demonstrate as much potential due to its lack of clinical superiority over other existing prostacyclin-based therapies.”
The key player believes that pharmaceutical companies should address unmet needs by focusing their attention on PAH-specific mechanisms which, although wrought with a high risk of failure, could potentially lead to innovative and effective disease-modifying treatments.
*OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024
This report provides analysis of the Pulmonary Arterial Hypertension (PAH) therapeutics space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2014 and forecast to 2024. It discusses market characterization, unmet needs, clinical trial mapping and implications for the PAH treatment arena.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News